Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 5, Issue 8, 2023

Research Progress on the Regulation of Intestinal Flora by Traditional Chinese Medicine in the Treatment of Metabolic Associated Fatty Liver Disease

Download as PDF

DOI: 10.23977/medcm.2023.050807 | Downloads: 16 | Views: 489

Author(s)

Yuanjing Xie 1, Jianmei Hao 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Xi'an Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi, 710021, China

Corresponding Author

Jianmei Hao

ABSTRACT

Metabolic associated fatty liver disease (MAFLD) is a metabolic syndrome manifestation in the liver, and its pathogenesis has not been fully elucidated. Numerous studies have shown that the development of MAFLD is closely related to intestinal flora dysbiosis, and intestinal flora is considered a new target for clinical treatment of MAFLD. At present, the efficacy of traditional Chinese medicine (TCM) in treating MAFLD based on intestinal flora is widely recognised, and the authors summarised the research on the regulation of intestinal flora by TCM in the treatment of MAFLD in recent years, in the hope that it will be helpful to the treatment and research of MAFLD. 

KEYWORDS

Metabolic associated fatty liver disease; Intestinal flora; Traditional Chinese medicine monomer; Traditional Chinese medicine compound

CITE THIS PAPER

Yuanjing Xie, Jianmei Hao, Research Progress on the Regulation of Intestinal Flora by Traditional Chinese Medicine in the Treatment of Metabolic Associated Fatty Liver Disease. MEDS Chinese Medicine (2023) Vol. 5: 48-55. DOI: http://dx.doi.org/10.23977/medcm.2023.050807.

REFERENCES

[1] Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J, 2020; 50(9):1038-1047. 
[2] Eslam M, Ratziu V, George J, etal. A new definition for metabolic associated fatty liver disease: An international expert consensus statement [J]. Hepatol, 2020. 
[3] Zeng Jing, Fan Jiangao. Clinical significance of renaming nonalcoholic fatty liver disease [J]. Journal of Clinical Hepatology, 2020, 36(06):1205-1207. 
[4] Golabi P, Paik JM, AlQahtani S, et al. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019[J]. J Hepatol, 2021, 75(4): 795-809. 
[5] Guo Liang, Tang Qiqun. Research progress of the mechanism and therapy of non-alcoholic fatty liver disease [J]. Chinese Bulletin of Life Sciences, 2018, 30(11):1165-1172. 
[6] Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways [J]. Curr Hepatol Rep, 2018, 17(4):350-360. 
[7] Cui Y, Wang Q, Chang R, et al. Intestinal barrier function nonalcoholic fatty liver disease interactions and possible role of gut microbiota[J]. J Agric Food Chem, 2019, 67(10): 2754-2762. 
[8] Mandato C, Delli Bovi AP, Vajro P. The gut-liver axis as a target of liver disease management. Hepatobiliary Surg Nutr, 2021, 10(1):100-102. 
[9] Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in nonalcoholic fatty liver disease [J]. Children (Basel), 2017, 4(8): 66. 
[10] Di Ciaula A, Baj J, Garruti G, et al. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk [J]. J Clin Med, 2020, 9(8): 42-46. 
[11] Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol, 2021, 18(1):4-17. 
[12] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy [J]. J Hepatol, 2020, 72 (3):558-577. 
[13] Liu Huiwei, Ye Hua. The role of gut microbiota in the pathogenesis of nonalcoholic fatty liver disease [J]. China Modern Doctor, 2019, 57(06):163-168. 
[14] Gao Mingyue, Yang Yakun, Yin Yanan, et al. Research advances in the pathogenesis of non-alcoholic fatty liver mediated by intestinal flora [J]. Medical Journal of Chinese People's Liberation Army, 2020, 45(09):990-995. 
[15] Chu Yanqing, Chu Xiaofeng. Application of Laboratory Animals in the Study of Intestinal Flora and Nonalcoholic Fatty Liver Disease [J]. Laboratory Animal Science, 2023, 40(01):87-92. 
[16] Liu Qiaohong, Zhao Yu, Hu Yiyang. Research Progress of Intestinal Microbiota Regulation in the Treatment of Nonalcoholic Fatty Liver [J]. World Chinese Medicine, 2020, 15(07):1075-1079. 
[17] Li Hongshan, Xi Yingfei, He Zheyun. Preventive and therapeutic effects of HJJB Formula on non-alcoholic steatohepatitis in mice and its influence on intestinal bacteria [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2022, 37(10):6014-6018. 
[18] He Pengfei, Ni kai, Qiu Jianghong, et al. Progress of clinical research on the inhibition of nonalcoholic fatty liver by Chinese herbal compounds [J]. Yunnan Journal of Traditional Chinese Medicine and Materia Medica, 2022, 43(09):87-91. 
[19] Li Yan, Zhu Weize, Li Houkai. Research progress of traditional Chinese medicine formulas and active compounds in the treatment of non-alcoholic fatty liver disease by regulating gut microbiota [J]. Acta Pharmaceutica Sinica, 2022, 57(12):3451-3464I0003
[20] Luo Hanyan. Study on the mechanism of "liver cleansing" by cassia seed based on the correlation between intestinal flora and intestinal-liver axis [D]. China Academy of Chinese Medical Sciences, 2020. 
[21] Hou Q K, Zhu S L, Zhang C R, et al. Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice [J]. Biomed Pharmacother, 2019, 118:109206. 
[22] Li Lu, Wang Yulin, Qin Hongyu, et al. Research progress on berberine in treatment of nonalcoholic fatty liver disease by regulating gut-liver axis [J]. Chinese Traditional and Herbal Drugs, 2021, 52(05):1501-1509. 
[23] Gong Zhiqiang, Han Sha, Huang Yanhong, et al. Effects of Ganoderma lucidum total naphthoquinone on nonalcoholic fatty liver mice and their intestinal flora [J]. Chinese Traditional Patent Medicine, 2023, 45(03):949-954. 
[24] Li Y, Liu T, Yan C, et al. Diammonium glycyrrhizinate protects against nonalcoholic fatty liver disease in mice through modulation of gut microbiota and restoration of intestinal barrier [J]. Mol Pharm, 2018, 15(9): 3860-3870. 
[25] Zhong Fangwei, Li Gengxi, Zeng Li. Gynostemma pentaphyllum saponins alleviate non-alcoholic fatty liver disease in rats by regulating intestinal flora and short-chain fatty acid metabolism [J]. China Journal of Chinese Materia Medica, 2022, 47(09):2500-2508. 
[26] Xie Weining, Peng Hongbing, Li Ye, et al. Liver with Liver Stagnation and Spleen Deficiency Syndrome and Intestinal Microflora [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2021, 27(03):129-137. 
[27] Li Zihui, Zhang Na, Wang Yu, et al. Mechanism of Yinchenhao Decoction in treating non-alcoholic fatty liver based on 16S rRNA technique and metabonomics [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2019, 34(05):1908-1913. 
[28] Luo Huabing, He Wenzhong, Li Dongsheng, et al. Clinical Effect of Jiawei Yinchenhao Decoction on Nonalcoholic Fatty Liver Disease and Its Influence on Intestinal Flora [J]. World Journal of Integrated Traditional and Western Medicine, 2021, 16(09):1746-1750. 
[29] Yan Baofei, Yuan Peng, Liu Shengjin, et al. Effects of Huangqin Decoction on gut microbiota in rats with nonalcoholic fatty liver disease [J]. Chinese Traditional and Herbal Drugs, 2022, 53(01):162-175. 
[30] Liu Y Y, Tan Y Y, Huang J Q, et al. Revealing the mechanism of Huazhi Rougan Granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology [J]. Front Pharmacol, 2022, 13: 875700. 
[31] Zhu Chunsheng, Shi Yamin, Fu Zhihui, et al. Mechanism of Huazhi Rougan Granule in treatment of non-alcoholic fatty liver disease based on intestinal flora and metabolomics [J]. Chinese Traditional and Herbal Drugs, 2023, 54(04):1190-1200. 
[32] Zhang Yuxiang, Wang Yiqiang, Jiang Demin, et al. Effects of Liver-clearing Damp-eliminating Blood-activating Prescription on Intestinal Flora in Nonalcoholic Fatty Liver Disease Rats [J]. Western Journal of Traditional Chinese Medicine, 2022, 35(03):19-22. 
[33] Ling Qihua, Wu Di, Le Min, et al. Study on mechanism of Cangju Qinggan Formula in treatment of non-alcoholic fatty liver based on "liverbile acid-intestinal microecology"[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine, 2022, 36(S1):143-148. 

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4363
Visits: 174296

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.